Clinical trials in Bottrop

Extensive clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, evaluating innovative therapeutic approaches.

• Early-stage breast cancer treatments
• Metastatic disease management
• Targeted therapy combinations

Studies include evaluation of novel drugs like ribociclib, elacestrant, and olaparib in combination with endocrine therapy.

Research investigating immunotherapy combinations and novel treatment approaches for patients with triple-negative breast cancer.

• Post-surgery treatment optimization
• Combination therapy assessment
• Survival outcome improvements

Clinical trials evaluating sacituzumab govitecan-hziy with pembrolizumab versus standard treatments.

Investigations into treatment strategies for advanced ovarian cancer, including peritoneal and fallopian tube cancers.

• First-line therapy optimization
• Combined treatment approaches
• Progressive disease management

Focus on evaluating niraparib and bevacizumab combinations following chemotherapy.